Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chafic Karam

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Muscle & Nerve|November 22, 2023
Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse eventsMadeline Singer, Sami Khella, Shawn Bird, et al.
Muscle & Nerve|June 29, 2022
Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersenChafic Karam, Duncan Brown, Min Yang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 26, 2013
Immune-mediated neuropathies following stem cell transplantationChafic Karam, Michelle L Mauermann, Patrick B Johnston, et al.
JAMA Cardiology|September 16, 2020
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in HistoryAhmad Masri, Hongya Chen, Catherine Wong, et al.
BMC Neurology|February 13, 2021
Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysisXiaochen Lin, Aaron Yarlas, Montserrat Vera-Llonch, et al.
Neurology|April 17, 2015
Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndromeChafic Karam, Christopher J Klein, Angela Dispenzieri, et al.
Orphanet Journal of Rare Diseases|May 9, 2024
Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studyTaha N Qarni, Felipe J S Jones, Brian Drachman, et al.
Neurology|August 1, 2023
Pearls & Oy-sters: Case Report of a Patient With Adult-Onset Thymidine Kinase 2 Gene DeficiencyJennifer Morganroth, Lovisa Ljungberg, Amy Goldstein, et al.
Muscle & Nerve|January 4, 2024
Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of expertsChafic Karam, Michelle L Mauermann, Alejandra Gonzalez-Duarte, et al.
Muscle & Nerve|July 8, 2022
Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trialChafic Karam, Duncan Brown, Min Yang, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Muscle & Nerve|November 22, 2023
Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse eventsMadeline Singer, Sami Khella, Shawn Bird, et al.
Muscle & Nerve|June 29, 2022
Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersenChafic Karam, Duncan Brown, Min Yang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 26, 2013
Immune-mediated neuropathies following stem cell transplantationChafic Karam, Michelle L Mauermann, Patrick B Johnston, et al.
JAMA Cardiology|September 16, 2020
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in HistoryAhmad Masri, Hongya Chen, Catherine Wong, et al.
BMC Neurology|February 13, 2021
Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysisXiaochen Lin, Aaron Yarlas, Montserrat Vera-Llonch, et al.
Neurology|April 17, 2015
Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndromeChafic Karam, Christopher J Klein, Angela Dispenzieri, et al.
Orphanet Journal of Rare Diseases|May 9, 2024
Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studyTaha N Qarni, Felipe J S Jones, Brian Drachman, et al.
Neurology|August 1, 2023
Pearls & Oy-sters: Case Report of a Patient With Adult-Onset Thymidine Kinase 2 Gene DeficiencyJennifer Morganroth, Lovisa Ljungberg, Amy Goldstein, et al.
Muscle & Nerve|January 4, 2024
Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of expertsChafic Karam, Michelle L Mauermann, Alejandra Gonzalez-Duarte, et al.
Muscle & Nerve|July 8, 2022
Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trialChafic Karam, Duncan Brown, Min Yang, et al.
Pageof 12